Tarlatamab (Tarlatamab)-Imdelltra Where can I buy it in the country and an explanation of the formal purchasing channels

Tarlatamab (trade name Imdelltra) is a new type of targeted therapy drug, mainly used for the treatment of indications such as small cell lung cancer (SCLC). Recently, the drug has been approved by the FDA in the United States and will be officially launched in May 2024. The specifications listed overseas include 1mg and 10mg, with prices of approximately 25,000 yuan and 148,000 yuan respectively. There are currently no generic drugs available. Domestically, talatumumab has submitted a marketing application, but it has not yet been officially launched. Therefore, patients cannot purchase it through conventional channels in China, nor can they enjoy medical insurance reimbursement.

Since it is not yet on the market in China, the formal purchase of talatumumab mainly relies on overseas channels. If patients really need to use the drug, they can obtain it through regular international drug import companies or participate in international clinical trials. Such channels usually require doctor's prescriptions, patient medical records, and compliant import procedures to ensure that the source of drugs is legal and safe. At the same time, patients should avoid purchasing through informal channels to prevent drug quality from substandard or the risk of counterfeiting.

Regarding domestic drug purchase channels after its launch in the future, it is expected that talatumumab will be mainly provided through oncology departments or specialty pharmacies in large tertiary hospitals, and may be included in medical insurance negotiations or payment management based on disease type to reduce patient burden. Prior to this, domestic patients should pay close attention to drug approval progress and official announcements, communicate with their attending doctors in a timely manner, and understand future drug purchase and usage plans in order to plan treatment appropriately.

Overall, talatumumab has not yet been launched in China, and formal channels are limited. Overseas purchases must go through legal institutions and comply with relevant laws and regulations. While waiting for domestic launch, patients should maintain the continuity of treatment plans, communicate closely with doctors, and pay attention to the latest information on drug listing and medical insurance policies to ensure that the drug can be obtained and used safely and compliantly after it is officially launched.

Reference materials:https://www.drugs.com/